The groundbreaking rise of Viagra has long been a benchmark of pharmaceutical success, but its legacy within the broader sector now raises questions about long-term returns . Copycat versions are diminishing exclusivity , leading to worries that betting on companies heavily reliant to Viagra's once-dominant position could be a problematic move , es